Primary Cytoreductive Surgery Versus Interval Debulking Surgery Following Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer: An Institutional Review

被引:2
|
作者
Ahmad, Zeeshanuddin [1 ]
Jain, Amar [1 ]
Mehta, Nikhil [1 ]
Saldanha, Elroy [1 ]
Patel, Dhruv [1 ]
Desai, Sanjay M. [1 ]
机构
[1] Sri Aurobindo Med Coll & Post Grad Inst, Dept Surg Oncol, Indore, Madhya Pradesh, India
关键词
Epithelial ovarian cancer (EOC); Primary cytoreductive surgery (PCS); Interval debulking surgery (IDS); Neoadjuvant chemotherapy (NACT); ADVANCED-STAGE OVARIAN; EXPLORATORY ANALYSIS; SURVIVAL; CARCINOMA; TIME;
D O I
10.1007/s40944-018-0253-2
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
ObjectiveTo compare theoverall survival of women with advanced-stage EOC treated by PCS versus NACT followed by IDS.Design, Setting, and ParticipantsRetrospective study of women with stage IIB-IVA ovarian carcinoma FIGO staging diagnosed between 2016 and 2018 treated at Department of Surgical Oncology, Sri Aurobindo Medical College and Post Graduate Institute, Indore.ExposuresInitial treatment approach of PCS versus NACT+IDS, examined using an intent-to-treat analysis.ResultsThe median follow-up was 18months (10-36months) in both groups. The median overall survival was 38months in PCS group and 31months in NACT group. Postoperative complications were seen more often in PCS group (11.3%) against 3.33% in NACT group. Patients with residual disease (microscopic and macroscopic residual disease) had poorer prognosis.ConclusionsPrimary cytoreductive surgery is associated with improved survival compared with NACT in otherwise healthy women with bulky epithelial ovarian. The biggest risk associated with the use of NACT is that patients with significant side effects and refractory disease will lose the opportunity for initial surgery. The lower survival in women receiving NACT can be owed to limited performance status in women undergoing NACT.
引用
收藏
页数:4
相关论文
共 50 条
  • [31] Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer
    Sinukumar, Snita
    Damodaran, Dileep
    Ray, Mukurdipi
    Mehta, Sanket
    Paul, Lista
    Bhatt, Aditi
    EJSO, 2021, 47 (06): : 1427 - 1433
  • [32] Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer
    Galaal, Khadra
    Naik, Raj
    Bristow, Robert E.
    Patel, Amit
    Bryant, Andrew
    Dickinson, Heather O.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (06):
  • [33] Primary Debulking Surgery vs Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer
    Cowan, Renee A.
    Chi, Dennis S.
    Fagotti, Anna
    Scambia, Giovanni
    ONCOLOGY-NEW YORK, 2017, 31 (06): : 453 - +
  • [34] Timing and Pattern of Recurrence in Ovarian Cancer Patients with High Tumor Dissemination Treated with Primary Debulking Surgery Versus Neoadjuvant Chemotherapy
    Petrillo, M.
    Ferrandina, G.
    Fagotti, A.
    Vizzielli, G.
    Margariti, P. A.
    Pedone, Anchora L.
    Nero, C.
    Fanfani, F.
    Scambia, Giovanni
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (12) : 3955 - 3960
  • [35] Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase
    Tran, Arthur-Quan
    Erim, Daniel O.
    Sullivan, Stephanie A.
    Cole, Ashley L.
    Barber, Emma L.
    Kim, Kenneth H.
    Gehrig, Paola A.
    Wheeler, Stephanie B.
    GYNECOLOGIC ONCOLOGY, 2018, 148 (02) : 329 - 335
  • [36] Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy
    Jorgensen, Kirsten
    Melamed, Alexander
    Wu, Chi-Fang
    Nitecki, Roni
    Pareja, Rene
    Fagotti, Anna
    Schorge, John O.
    Ramirez, Pedro T.
    -Hain, Jose Alejandro Rauh
    GYNECOLOGIC ONCOLOGY, 2023, 172 : 130 - 137
  • [37] The Role of Diaphragmatic Surgery During Interval Debulking After Neoadjuvant Chemotherapy An Analysis of 74 Patients With Advanced Epithelial Ovarian Cancer
    Tsolakidis, Dimitris
    Amant, Frederic
    Van Gorp, Toon
    Leunen, Karin
    Neven, Patrick
    Vergote, Ignace
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (04) : 542 - 551
  • [38] Primary Surgery or Interval Debulking for Advanced Epithelial Ovarian Cancer: Does It Matter?
    Markauskas, Algirdas
    Mogensen, Ole
    Christensen, Rene dePont
    Jensen, Pernille Tine
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (08) : 1420 - 1428
  • [39] Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer
    Colombo, P. E.
    Labaki, M.
    Fabbro, M.
    Bertrand, M.
    Mourregot, A.
    Gutowski, M.
    Saint-Aubert, B.
    Quenet, F.
    Rouanet, P.
    Mollevi, C.
    GYNECOLOGIC ONCOLOGY, 2014, 135 (02) : 223 - 230
  • [40] Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery
    Muraji, Miho
    Sudo, Tamotsu
    Iwasaki, Shin-ichi
    Ueno, Sayaka
    Wakahashi, Senn
    Yamaguchi, Satoshi
    Fujiwara, Kiyoshi
    Nishimura, Ryuichiro
    GYNECOLOGIC ONCOLOGY, 2013, 131 (03) : 531 - 534